← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

Traditional approvalTraditional conversionClassical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Traditional approval of the 400 mg every-six-weeks IV dosing option for eligible adults with classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma under the existing indications.

LAMPGEN ANALYSIS

Why it matters

The conversion resolves the earlier accelerated approval for the less frequent lymphoma dosing schedule.

What research teams should watch

Keep lymphoma dosing pathways distinct from pediatric schedules and document the intended regimen and visit interval.

PRIMARY RECORDS

Sources